Riskpilot← Back to searchSign inGet full accessGK PHARMA ApS
APSActiveCVR 81267316Egøjevej 162CManufacture of perfumes and toilet preparations · NACE 2042Est. 197720 employees
Revenue 2024
DKK 3,8M
+19% vs 2023
EBITDA margin
35.0%
+8% vs 2023
Equity ratio
23.2%
Financial strength
Net profit 2024
DKK 954K
+11% vs 2023
| Revenue | DKK 3,8M | +19% |
| EBITDA | DKK 1,3M | +8% |
| Net profit | DKK 954K | +11% |
| Total assets | DKK 9,6M | -7% |
| Equity | DKK 2,2M | +5% |
| Employees | 20 | — |
Legal name
GK PHARMA ApS
CVR number
81267316
Legal form
Anpartsselskab
NACE code
2042 · Manufacture of perfumes and toilet preparations
Founded
22. september 1977
Share capital
DKK 200.000
Employees
20 (FTE)
VAT registered
Yes
Audit selected
Yes
Last report
2024-12-31
Financial year
January – December
Signatory rights
Selskabet tegnes af to medlemmer af bestyrelsen i forening eller af en direktør alene.
Company purpose
Selskabets formål er at drive fabrikation af veterinærmedicin, kosmetiske produkter og der med beslægtet virksomhed samt handels-, financierings- og investeringsvirksomhed.
Address
Egøjevej 162C
Phone
+4556217256
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 7.685 | 7.732 | 9.257 | 8.409 | 7.480 | 8.829 | 9.049 | 9.631 | 13.993 | 16.711 | 3.926 | 3.214 | 3.823 |
| Staff expenses | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 |
| EBITDA | 81 | 79 | -741 | 208 | 178 | 579 | 411 | 934 | 1.839 | 2.066 | 1.480 | 1.237 | 1.338 |
| Depreciation & amort. | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 |
| EBIT | 81 | 79 | -741 | 208 | 178 | 579 | 411 | 934 | 1.839 | 2.066 | 1.480 | 1.237 | 1.338 |
| Net financials | -42 | -23 | -48 | -81 | -33 | -20 | -17 | -21 | -52 | -58 | -164 | -108 | -105 |
| Profit before tax | 40 | 74 | -1.012 | 163 | 145 | 559 | 395 | 913 | 1.788 | 2.008 | 1.316 | 1.129 | 1.233 |
| Tax | 10 | -0 | -0 | -0 | 32 | 123 | 87 | 201 | 403 | 446 | 310 | 267 | 278 |
| Net profit | 30 | 56 | -790 | 127 | 113 | 436 | 308 | 712 | 1.385 | 1.563 | 1.007 | 862 | 954 |
| Item | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 2.733 | 2.505 | 3.302 | 2.888 | 2.463 | 2.654 | 3.006 | 3.535 | 6.053 | 4.782 | 10.470 | 10.333 | 9.615 |
| Equity | 258 | 314 | -476 | -349 | -236 | 200 | 508 | 912 | 1.585 | 1.763 | 1.266 | 2.128 | 2.232 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1.983 | 1.614 | 1.243 |
| Short-term debt | 2.475 | 2.191 | 3.778 | 3.238 | 2.699 | 2.454 | 2.498 | 2.622 | 4.469 | 3.020 | 7.221 | 6.591 | 6.140 |
| Total debt | 2.475 | 2.191 | 3.778 | 3.238 | 2.699 | 2.454 | 2.498 | 2.622 | 4.469 | 3.020 | 9.204 | 8.205 | 7.383 |
EBITDA margin
35.0%
This company
15.8%
Market median
+122% vs market
20122024
Equity ratio
23.2%
This company
38.2%
Market median
-39% vs market
20122024
Return on equity
42.7%
This company
18.4%
Market median
+132% vs market
20122024
Net profit margin
25.0%
This company
8.1%
Market median
+209% vs market
20122024
Asset turnover
0.40×
This company
1.12×
Market median
-64% vs market
20122024
Debt / equity
3.31×
This company
0.62×
Market median
-434% vs market
20122024
- Annual report 2024Filed via CVR / Virk · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via CVR / Virk · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via CVR / Virk · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via CVR / Virk · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via CVR / Virk · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via CVR / Virk · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via CVR / Virk · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via CVR / Virk · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via CVR / Virk · Period 2016-01-01 – 2016-12-31
- Annual report 2015Filed via CVR / Virk · Period 2015-01-01 – 2015-12-31
- Annual report 2014Filed via CVR / Virk · Period 2014-01-01 – 2014-12-31
- Annual report 2013Filed via CVR / Virk · Period 2013-01-01 – 2013-12-31
- Annual report 2012Filed via CVR / Virk · Period 2012-01-01 – 2012-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
AJ Management | Management | 2012 | — | — |
LS Chief Executive Officer | Chief Executive Officer | 2014 | — | — |
ER Management | Management | 1996 | — | — |
KG Chief Executive Officer | Chief Executive Officer | 2017 | — | — |
EV Management | Management | 1977 | — | — |
HK Chief Executive Officer | Chief Executive Officer | 2003 | — | — |
ER Management | Management | 1977 | — | — |
HE | Audit | 1977 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2003 | — | — | |
| Board of Directors | 2007 | — | — | |
| Board of Directors | 1996 | — | — | |
| Board of Directors | 2005 | — | — | |
| Chairman | 2023 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
Salvefabrikken ApS | Company | 100.0% | 100.0% | 2022 |
| Individual | 50.0% | 50.0% | 1977 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Salvefabrikken ApS
GK PHARMA ApS Board members of GK PHARMA ApS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Andrew John Reks Jacobsen | Management | 0 companies |
| Lars Skov Ibsen | Chief Executive Officer | 0 companies |
| Erik Rasmussen | Management | 0 companies |
| Klaus Groth | Chief Executive Officer | 0 companies |
| Erik Vagn Thomsen | Management | 0 companies |
| Henrik Kjærsgaard Nielsen | Chief Executive Officer | 0 companies |
| Eigil Rechnagel | Management | 0 companies |
| Hans Erik Frederiksen | Audit | 0 companies |
| Ole Haslund | Board of Directors | 0 companies |
| Trine Bente Kjems | Board of Directors | 0 companies |
| Peter Neergaard | Board of Directors | 0 companies |
| Ole Kristensen | Board of Directors | 0 companies |
| Dorthe Groth | Chairman | 0 companies |